Keros Therapeutics Files 8-K
Ticker: KROS · Form: 8-K · Filed: Jan 30, 2025 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | Jan 30, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
TL;DR
Keros filed a routine 8-K, no major news.
AI Summary
Keros Therapeutics, Inc. filed an 8-K on January 30, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific details about new events, financial figures, or material agreements beyond its routine reporting nature.
Why It Matters
This filing indicates Keros Therapeutics is fulfilling its regulatory reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for regulatory disclosure and does not contain information that would immediately impact the company's risk profile.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- January 30, 2025 (date) — Date of earliest event reported
- 1050 Waltham Street, Suite 302 (address) — Principal executive offices
- Lexington, Massachusetts (location) — Principal executive offices location
- 02421 (zip_code) — Principal executive offices zip code
- 617-314-6297 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Keros Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits, as indicated by the 'ITEM INFORMATION' section.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing occurred on January 30, 2025.
What is the exact name of the registrant filing this report?
The exact name of the registrant is Keros Therapeutics, Inc.
Where are Keros Therapeutics, Inc.'s principal executive offices located?
Keros Therapeutics, Inc.'s principal executive offices are located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
What is the SEC file number for Keros Therapeutics, Inc.?
The SEC file number for Keros Therapeutics, Inc. is 001-39264.
Filing Stats: 576 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-01-30 08:01:29
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto
Filing Documents
- kros-20250130.htm (8-K) — 37KB
- exhibit99113025pr.htm (EX-99.1) — 5KB
- 0001664710-25-000010.txt ( ) — 168KB
- kros-20250130.xsd (EX-101.SCH) — 2KB
- kros-20250130_lab.xml (EX-101.LAB) — 22KB
- kros-20250130_pre.xml (EX-101.PRE) — 13KB
- kros-20250130_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 30, 2025, Keros Therapeutics, Inc. (the "Company") issued a press release announcing that Jasbir Seehra, the Company's Chair and Chief Executive Officer, will participate in a fireside chat presentation at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025 at 10:00 a.m. Eastern time. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated January 30 , 2025. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: January 30, 2025